The authors demonstrated that both genetic or pharmacological inhibition of SRPK1 prolonged the survival of murine AML models by altering the splicing of several leukemogenesis-associated genes including MYB, MED24 and BRD4 (22). Here, SRPK1 is linked to acute myeloid leukemia.